Connect Biopharma Holdings (CNTB) Net Income towards Common Stockholders (2024 - 2026)
Connect Biopharma Holdings (CNTB) posted quarterly Net Income towards Common Stockholders of -$19.4 million for Q1 2026, down 88.84% year-on-year from -$173.9 million in Q1 2025, and down 28.39% on a QoQ basis from -$15.1 million in Q4 2025.
Connect Biopharma Holdings (CNTB) Net Income towards Common Stockholders (2024 - 2026) Analysis & Trends
Connect Biopharma Holdings (CNTB) has reported Net Income towards Common Stockholders for 3 consecutive years, with -$19.4 million the latest figure, recorded in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 88.84% year-over-year to -$19.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$64.6 million (down 275.46% YoY) and the FY2025 annual result came in at -$55.5 million, down 255.0% from the prior year.
- Net Income towards Common Stockholders eased to -$19.4 million in Q1 2026 per CNTB's latest filing, from -$15.1 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for CNTB reached as high as $14.8 million in Q2 2024 and fell as low as -$19.4 million in Q1 2026.
- A 3-year average of -$10.1 million and a median of -$12.9 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- The largest YoY upside for Net Income towards Common Stockholders was 18.16% in 2025 against a maximum downside of 186.88% in 2025.
- Year by year, Net Income towards Common Stockholders stood at -$8.9 million in 2024, then plunged by 69.65% to -$15.1 million in 2025, then dropped by 28.39% to -$19.4 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$19.4 million, -$15.1 million, and -$17.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,015.37 Bn | 1,015.37 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.39 Bn | 466.59 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 122.52 Bn | 115.28 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 70.33 Bn | 61.58 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | -0.68 |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Connect Biopharma Holdings | 121.57 Mn | 121.57 Mn | - | -19.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.40 Mn |
| Dec 31, 2025 | -15.11 Mn |
| Sep 30, 2025 | -17.20 Mn |
| Jun 30, 2025 | -12.90 Mn |
| Mar 31, 2025 | -10.27 Mn |
| Dec 31, 2024 | -8.91 Mn |
| Sep 30, 2024 | -12.88 Mn |
| Jun 30, 2024 | 14.85 Mn |
| Mar 31, 2024 | -8.69 Mn |